Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation

Bone Marrow Transplant. 2016 Jul;51(7):985-7. doi: 10.1038/bmt.2016.16. Epub 2016 Feb 15.

Authors

K Ishiyama¹, J Takeda¹, T Kondo¹, N Sugimoto^{1

2}, H Kawabata¹, T Kitano¹, A Takaori-Kondo¹

Affiliations

¹ Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.

PMID: 26878662
DOI: 10.1038/bmt.2016.16

No abstract available

MeSH terms

Adolescent
Adult
Antineoplastic Agents / administration & dosage
Blood Platelets / cytology
Cord Blood Stem Cell Transplantation / methods*
Feasibility Studies
Female
Graft Rejection / therapy*
Hematopoietic Stem Cell Transplantation
Humans
Male
Melphalan / administration & dosage*
Middle Aged
Neutrophils / cytology
Retrospective Studies
Salvage Therapy / methods*
Time Factors
Transplantation Conditioning
Treatment Outcome
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives*
Whole-Body Irradiation / methods*

Substances

Antineoplastic Agents
Vidarabine
fludarabine
Melphalan